Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (538)	3/7/2005 2:47:06 PM
From: Icebrg	Read Replies (2) of 946

It is not only a matter of alopecia. Not being based on Cremafore is another advantage. Less pain, cardiac side-effects (?) and neurotoxicities a third. Clearly, these patients deserve a "milder" type of chemotherapy if such a thing is available, costs notwithstanding. Seeing FDA approve Abraxane on what appeared to be even flimsier support from its registration trial means that eventually an approval should not be ruled out, as long as CTIC is somehow able to make the argument for non-inferiority stick. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next